Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Dulera by Year
Dulera (mometasone/formoterol, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)
Merck Dulera: $214M in FY2018, down 25.4% from a year earlier. No newer figure appears in the documents we track.
Where the FY2018 figure comes from
Source: Form 10-K (filed 2019-02-27) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Dulera (mometasone/formoterol, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2018 | Dec 31, 2018 | 214 | -25.4% | Form 10-K (filed 2019-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 287 | -34.2% | Form 10-K (filed 2019-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 436 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up dulera
Cite this data
StockData. (2026). Merck Dulera ($M), annual FY2016–FY2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-dulera
See every metric in the Merck KPI table. Data updated Oct 26, 2026.